<DOC>
	<DOCNO>NCT03085173</DOCNO>
	<brief_summary>The purpose phase I study test safety different dose level specially prepared cell collect patient call `` modified T cell '' . The investigator want find safe dose modify T cell patient type cancer progress standard therapy . The investigator also want find effect modify T cell patient cancer .</brief_summary>
	<brief_title>A Trial `` Armored '' CAR T Cells Targeting CD19 For Patients With Relapsed CLL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Patients must CD19+ CLL either relapse refractory disease , define : Refractory relapse least 2 prior chemo chemoimmunotherapy ( e.g . FCR , BR ) require treatment Refactory relapse least 1 prior biologic agent ( e.g . Ibrutinib , idelaslisib , venetoclax , except single agent antiCD20 monoclonal antibody ) require treatment Age ≥ 18 year age Creatinine ≤2.0 mg/100 ml , direct bilirubin ≤2.0 mg/100 ml , AST ALT ≤3.0x upper limit normal ( ULN ) Adequate pulmonary function assess ≥92 % oxygen saturation room air pulse oximetry Karnofsky performance status &lt; 70 Pregnant lactate woman . Women men childbearing age use effective contraception study continue 1 year treatment finish Impaired cardiac function ( LVEF &lt; 40 % ) assess ECHO MUGA scan Patients active know autoimmune disease ineligible Patients follow cardiac condition exclude : New York Heart Association ( NYHA ) stage III IV congestive heart failure Patients uncontrolled systemic fungal , bacterial , viral infection ineligible Patients concurrent active malignancy define malignancy require therapy expectant observation hormonal therapy , exception squamous basal cell carcinoma skin Patients history presence clinically significant neurological disorder epilepsy , generalized seizure disorder , severe brain injury ineligible Any issue , opinion treat physician , would make patient ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>CAR T Cells Targeting CD19</keyword>
	<keyword>EGFRt/19-28z/4-1BBL</keyword>
	<keyword>16-1570</keyword>
</DOC>